Browse the evidence

GLP-1 receptor agonists (liraglutide, semaglutide, tirzepatide) produce significant, dose-dependent weight loss in adults with obesity, with tirzepatide demonstrating the highest efficacy.

If you have obesity, GLP-1 medications like semaglutide or tirzepatide are highly effective tools for weight loss, often outperforming lifestyle changes alone. The key to success is starting at the lowest dose and titrating up slowly to minimize gastrointestinal side effects, which usually subside over time. Consult a healthcare provider to determine if you are a candidate based on your BMI and health history.

Excess adiposity, particularly visceral fat, is the central driver of the Cardiovascular-Renal-Hepatic-Metabolic (CRHM) syndrome, leading to insulin resistance, inflammation, and multi-organ dysfunction.

Managing excess body fat, especially around the waist, is the most important step in preventing heart, kidney, and liver disease. Reducing visceral fat reduces inflammation and improves insulin sensitivity, protecting your organs.

Regular physical activity (150-300 min moderate or 75-150 min vigorous aerobic activity plus resistance training 2x/week) protects against age-associated weight gain and targets fat and muscle mass respectively.

Aim for at least 75 minutes of vigorous or 150 minutes of moderate aerobic exercise per week, plus two days of strength training. This combination is crucial for managing menopause-related fat gain and muscle loss.

GLP-1 receptor agonists (GLP-1 RAs) produce clinically meaningful weight loss of 15–20% in clinical trials, significantly exceeding the modest 3–9% loss from alternative pharmacotherapies and the partial regain seen with lifestyle interventions alone.

GLP-1 medications like semaglutide and tirzepatide are currently the most effective pharmacological tools for weight loss, achieving 15-20% body weight reduction. They work by targeting hormonal pathways to reduce appetite and improve metabolism. While lifestyle changes (diet and exercise) are foundational, they are often insufficient alone for sustained loss. These medications are taken weekly (or daily for liraglutide) and are intended for long-term use, as stopping them typically leads to significant weight regain. They are generally recommended for individuals with a BMI of 30 or higher, or 27 or higher with related health conditions.

Discontinuation of GLP-1 RA treatment leads to significant weight regain (up to 68% of lost weight) and reversal of cardiometabolic improvements, indicating that obesity requires chronic management.

If you stop taking GLP-1 medications, you will likely regain most of the weight you lost, along with your previous metabolic risks. This is because obesity is a chronic condition, not a temporary state. Just as you wouldn't stop blood pressure medication, you likely need to stay on GLP-1 therapy long-term to maintain your weight loss. The goal is sustained health, not a short-term fix.

Pharmaceutical interventions such as Tirzepatide and Semaglutide reduce obesity-related inflammation by promoting weight loss and directly modulating inflammatory pathways (e.g., reducing TNF-α, IL-6, and hs-CRP).

If lifestyle changes are insufficient, medications like Tirzepatide or Semaglutide can significantly reduce body weight and lower inflammatory markers. These are not just 'weight loss drugs' but treatments that address the underlying inflammation of obesity. Consult a doctor to see if you are a candidate.

Adherence to a Mediterranean diet reduces pro-inflammatory cytokines (TNF-α, IL-6, CRP) and improves gut microbiota composition, leading to weight loss and reduced systemic inflammation even without caloric restriction.

Adopting a Mediterranean-style diet—rich in vegetables, fruits, whole grains, and olive oil—can reduce inflammation and promote modest weight loss, even if you don't strictly count calories. Focus on food quality and gut health.

GLP-1 receptor agonists (e.g., semaglutide, liraglutide) and dual GIP/GLP-1 agonists (e.g., tirzepatide) induce significant weight loss and improve glycemic control by acting on multiple pathways including appetite suppression, delayed gastric emptying, and improved adipose tissue health.

GLP-1 agonists like semaglutide are FDA-approved for weight loss and diabetes. They work by mimicking gut hormones to reduce appetite and slow digestion. Clinical trials show significant weight loss (up to ~15% in some ranges) and improved blood sugar. They are typically taken once weekly.

Resistance training significantly increases whole-body muscle mass (fat-free, lean, and skeletal muscle mass) in healthy adult males, with an average gain of approximately 1.53 kg.

If you are a healthy adult male engaging in resistance training, you can expect to gain approximately 1.5 kg of whole-body muscle mass over a training period of 4 to 24 weeks. This gain is consistent regardless of your specific training experience level (untrained to advanced) or specific training variables like sets or intensity, though excessive sets per workout may negatively impact gains.

Long-term intensive lifestyle intervention (weight loss via caloric restriction and increased physical activity) significantly improves and preserves performance-based physical function (gait speed and lower extremity function) in overweight/obese middle-aged and older adults with type 2 diabetes, despite anticipated loss of lean mass.

For older adults with type 2 diabetes, aiming for modest weight loss (around 10%) and increasing physical activity to about 175 minutes per week can help maintain mobility and walking speed over the long term. This benefit persists even if you lose some muscle mass, so don't let the fear of 'losing muscle' stop you from trying lifestyle changes.

Dual GIP/GLP-1 receptor agonists (e.g., tirzepatide) produce significantly greater weight loss (up to 20.9%) compared to selective GLP-1 receptor agonists (e.g., semaglutide) by activating both GIP and GLP-1 signaling pathways in the brain and peripheral tissues.

If you have obesity and lifestyle changes alone haven't worked, a dual GIP/GLP-1 agonist like tirzepatide (Mounjaro/Mounjaro) is currently one of the most effective medical treatments available. It is taken as a once-weekly injection and can lead to nearly 21% body weight loss in clinical trials, which is significantly higher than older GLP-1 drugs. Be prepared for potential mild stomach issues during the first few months as your dose increases, but these often subside. This treatment is intended for adults with obesity or overweight with at least one weight-related condition.

Semaglutide 2.4 mg weekly produces significant weight loss (approx. 14.9%) in overweight and obese adults without diabetes, significantly outperforming placebo and older GLP-1 agonists like liraglutide.

Semaglutide 2.4 mg (Wegovy) is a once-weekly injection approved for chronic weight management in adults with obesity or overweight with at least one weight-related condition. Clinical trials show it can lead to an average 14.9% body weight loss over 68 weeks when combined with diet and exercise. This is significantly more effective than older GLP-1 drugs like liraglutide. Common side effects include nausea and diarrhea, which are usually mild and decrease over time.

Diets high in ultra-processed foods cause excess ad libitum energy intake and weight gain compared to minimally processed diets, even when macronutrients and presented calories are matched.

Prioritize whole, minimally processed foods. Even if you match the calories and macros, ultra-processed foods make you eat more because of their physical structure and hyper-palatability. Focus on food quality and processing level, not just nutrient numbers.

Barbell velocity and Reps in Reserve (RIR) based RPE are practical, reliable, and strongly correlated with resistance training performance, making them superior tools for autoregulating load and volume.

Use a barbell speed tracker or estimate your Reps in Reserve (RIR) to adjust your weights. If you are using RIR, stop a set when you feel you could only do 1-2 more reps with good form. This ensures you are training close to failure without excessive fatigue.

GLP-1 receptor agonists (specifically semaglutide and liraglutide) and dual GIP/GLP-1 agonists (tirzepatide) produce significant, dose-dependent weight loss in patients with type 2 diabetes, making them superior to weight-gain-promoting medications like insulin and sulfonylureas for weight-centric management.

If you have Type 2 Diabetes and struggle with weight, ask your doctor about GLP-1 agonists (like semaglutide) or dual agonists (like tirzepatide). These drugs not only control blood sugar but also promote significant weight loss (up to 15-20% in trials) by slowing digestion and reducing appetite, unlike older drugs like insulin which often cause weight gain.

Once-weekly subcutaneous semaglutide (2.4 mg) combined with lifestyle intervention significantly reduces body weight in adults with obesity or overweight.

If you have obesity or overweight with related health issues, ask your doctor about once-weekly semaglutide injections (2.4 mg). It works by suppressing appetite and slowing digestion, leading to significant weight loss (around 15% in trials) when combined with diet and exercise. Be aware of potential stomach issues like nausea, which often improve over time.

Ultra-processed diets cause increased energy intake and weight gain compared to unprocessed diets, likely due to modifications in the food matrix affecting satiety and nutrient bioavailability.

Be aware that ultra-processed foods are engineered to bypass normal satiety signals, leading to passive overconsumption. This is not a personal failure but a property of the food. To manage weight, prioritize foods that naturally promote satiety (whole foods) and limit UPF.

GLP-1 receptor agonists (liraglutide 3 mg, semaglutide 2.4 mg) and dual GLP-1/GIP agonists (tirzepatide 15 mg) produce significant, superior weight loss compared to placebo and older anti-obesity medications.

If you have obesity, newer GLP-1 or dual agonist medications (like semaglutide or tirzepatide) are significantly more effective for weight loss than older drugs or lifestyle changes alone. These require weekly or daily injections and work by mimicking hormones that control appetite and digestion. They are generally safe but require medical supervision, especially if you have a history of thyroid cancer or pancreatitis.

Cardiorespiratory fitness is a vital sign that strongly predicts reduced morbidity and mortality, and even small increases in fitness (1.0-1.5 METs) provide significant protective effects against chronic disease and premature death.

Focus on improving your cardiorespiratory fitness, as it is the strongest predictor of living longer and healthier. You don't need to be an elite athlete; even small improvements (equivalent to walking slightly faster or climbing a few flights of stairs) can significantly reduce your risk of heart disease, cancer, and premature death. Consider fitness a vital sign to track.

Treatment with GLP-1 receptor agonists (GLP-1 RAs) or dual GIP/GLP-1 receptor agonists (GIP/GLP-1 RAs) significantly reduces the risk of major adverse cardiovascular events (MACE) and all-cause mortality in overweight or obese adults without diabetes compared to placebo.

If you are overweight or obese and do not have diabetes, treatment with GLP-1 or GIP/GLP-1 receptor agonists (such as semaglutide, liraglutide, or tirzepatide) has been shown in large studies to significantly lower your risk of major heart events (like heart attack and stroke) and death from any cause compared to taking a placebo. This benefit exists independently of diabetes status.

Tirzepatide, a dual GLP-1/GIP receptor agonist, achieves superior HbA1c reduction (up to 2.6%) and weight loss (up to 15.7%) compared to other GLP-1 RAs and insulin, making it a highly effective treatment for T2D and obesity.

Tirzepatide is a once-weekly injection that targets both GLP-1 and GIP hormones. It is highly effective for lowering blood sugar (up to 2.6% HbA1c reduction) and promoting significant weight loss (up to 15.7%). It is more effective than many other GLP-1 RAs and insulin, making it a top-tier option for managing T2D and obesity, despite being an injection.

GLP-1 RAs promote significant weight loss (up to 18-21% in clinical trials) by acting on central brain regions to modify food preferences, reduce appetite, and increase satiety.

GLP-1 medications like semaglutide and tirzepatide are highly effective for weight loss, achieving 18-21% body weight reduction in clinical trials. They work by changing how your brain signals hunger and fullness, not just by making you feel full. This can be particularly helpful if you have struggled with dieting in the past. Combining the medication with behavioral therapy yields the best results.

GLP-1 receptor agonist therapies significantly reduce total cardiovascular events, major adverse cardiovascular events (MACE), and all-cause mortality in nondiabetic individuals with overweight or obesity compared to placebo.

For nondiabetic adults who are overweight or obese, using GLP-1 receptor agonist therapies (such as semaglutide, tirzepatide, or liraglutide) significantly lowers the risk of heart attacks, strokes, and death from any cause compared to placebo. This benefit exists independently of diabetes status, suggesting these drugs should be considered for cardiovascular risk reduction in this population, not just for weight loss.

New generation incretin analogues (semaglutide 2.4 mg weekly and tirzepatide 5-15 mg weekly) produce sustained mean weight reductions of 15-20% in adults with BMI ≥27 kg/m², significantly outperforming older agents and lifestyle interventions alone.

If you have a BMI over 27, talk to your doctor about semaglutide or tirzepatide. These are weekly injections (or oral pills for semaglutide) that help you lose 15-20% of your body weight, which is much more than older drugs. You must also follow a lifestyle plan with diet and exercise.